Bexagliflozin
Antidiabetic medication / From Wikipedia, the free encyclopedia
Bexagliflozin, sold under the brand name Brenzavvy, is an antidiabetic medication used to improve glycemic control in adults with type 2 diabetes.[3][4] It is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that is taken by mouth.[1][2]
Quick Facts Clinical data, Trade names ...
![]() | |
Clinical data | |
---|---|
Trade names | Brenzavvy, Bexacat |
AHFS/Drugs.com | Monograph |
MedlinePlus | a623027 |
License data | |
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
Chemical and physical data | |
Formula | C24H29ClO7 |
Molar mass | 464.94 g·mol−1 |
3D model (JSmol) | |
| |
|
Close
The most common side effects include genital yeast infections, urinary tract infections, and increased urination.[4]
Bexagliflozin was approved for medical use in the United States in January 2023.[4][5]